{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:50:29Z","timestamp":1785876629393,"version":"3.56.0"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T00:00:00Z","timestamp":1782432000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23fk0210093"],"award-info":[{"award-number":["JP23fk0210093"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24fk0210152"],"award-info":[{"award-number":["JP24fk0210152"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP24ck0106919"],"award-info":[{"award-number":["JP24ck0106919"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.canlet.2026.218695","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T16:36:07Z","timestamp":1782491767000},"page":"218695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["T-cell receptor\u2013engineered T-cell therapy using a glypican-3\u2013specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2\u2013positive glypican-3\u2013expressing cancers"],"prefix":"10.1016","volume":"657","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-5079","authenticated-orcid":false,"given":"Tsuyoshi","family":"Terada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7095-6556","authenticated-orcid":false,"given":"Toshihiro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunobu","family":"Ohnuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manami","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kayoko","family":"Shoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-7713-6888","authenticated-orcid":false,"given":"Yasunori","family":"Amaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaho","family":"Takeichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2161-1807","authenticated-orcid":false,"given":"Masashi","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Motokazu","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazumasa","family":"Takenouchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0679-1371","authenticated-orcid":false,"given":"Nobuo","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4468-5844","authenticated-orcid":false,"given":"Naoto","family":"Gotohda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachiko","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3918-2385","authenticated-orcid":false,"given":"Tetsuya","family":"Nakatsura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2026.218695_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.canlet.2026.218695_bib2","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218695_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid."},{"key":"10.1016\/j.canlet.2026.218695_bib4","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.canlet.2026.218695_bib5","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1159\/000516899","article-title":"Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with Anti-PD-1 antibody","volume":"10","author":"Morita","year":"2021","journal-title":"Liver Cancer"},{"key":"10.1016\/j.canlet.2026.218695_bib6","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/S1470-2045(16)30598-8","article-title":"Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's hepatic tumors international collaboration","volume":"18","author":"Meyers","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218695_bib7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.canlet.2026.218695_bib8","article-title":"The RELIVE consortium for relapsed or refractory pediatric hepatoblastoma and hepatocellular carcinoma: a scoping review of the problem and a proposed solution","volume":"69","author":"O'Neill","year":"2024","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.canlet.2026.218695_bib9","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1200\/JCO.2002.06.155","article-title":"Hepatocellular carcinoma in children and adolescents: results from the pediatric oncology group and the Children's cancer group intergroup study","volume":"20","author":"Katzenstein","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218695_bib10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1007\/s12029-020-00494-w","article-title":"Pediatric hepatocellular carcinoma","volume":"51","author":"Varol","year":"2020","journal-title":"J. Gastrointest. Cancer"},{"key":"10.1016\/j.canlet.2026.218695_bib11","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1002\/ijc.34453","article-title":"A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcoma","volume":"152","author":"Ishihara","year":"2023","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218695_bib12","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2026.218695_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/A:1025312819804","article-title":"The contribution of in vivo manipulation of gene expression to the understanding of the function of glypicans","volume":"19","author":"Filmus","year":"2002","journal-title":"Glycoconj. J."},{"key":"10.1016\/j.canlet.2026.218695_bib14","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1129483","article-title":"Phase II study of the GPC3-derived peptide vaccine as an adjuvant therapy for hepatocellular carcinoma patients","volume":"5","author":"Sawada","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218695_bib15","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejca.2010.10.024","article-title":"Glypican-3: a new target for cancer immunotherapy","volume":"47","author":"Ho","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.canlet.2026.218695_bib16","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1111\/j.1349-7006.2009.01206.x","article-title":"Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma","volume":"100","author":"Shirakawa","year":"2009","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218695_bib17","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1238542","article-title":"Efficacy of glypican-3-derived peptide vaccine therapy on the survival of patients with refractory ovarian clear cell carcinoma","volume":"5","author":"Suzuki","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.canlet.2026.218695_bib18","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1016\/j.ajpath.2018.05.014","article-title":"Glypican 3 overexpression across a broad spectrum of tumor types discovered with functional genomic mRNA profiling of a large cancer database","volume":"188","author":"Moek","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.canlet.2026.218695_bib19","doi-asserted-by":"crossref","first-page":"3686","DOI":"10.1158\/1078-0432.CCR-11-3044","article-title":"Phase I trial of a Glypican-3\u2013Derived peptide vaccine for advanced hepatocellular carcinoma: Immunologic evidence and potential for improving overall survival","volume":"18","author":"Sawada","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218695_bib20","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1377872","article-title":"Phase I study of glypican-3-derived peptide vaccine therapy for patients with refractory pediatric solid tumors","volume":"7","author":"Tsuchiya","year":"2018","journal-title":"OncoImmunology"},{"key":"10.1016\/j.canlet.2026.218695_bib21","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1349-7006.2011.01896.x","article-title":"HLA\u2010A2\u2010restricted glypican\u20103 peptide\u2010specific CTL clones induced by peptide vaccine show high avidity and antigen\u2010specific killing activity against tumor cells","volume":"102","author":"Yoshikawa","year":"2011","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218695_bib22","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1038\/mtna.2012.52","article-title":"A promising vector for TCR gene therapy: differential effect of siRNA, 2A peptide, and disulfide bond on the introduced TCR expression","volume":"1","author":"Okamoto","year":"2012","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.canlet.2026.218695_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/S0006-291X(03)00908-2","article-title":"Glypican-3, overexpressed specifically in human hepatocellular carcinoma, is a novel tumor marker","volume":"306","author":"Nakatsura","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.canlet.2026.218695_bib24","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-Cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.canlet.2026.218695_bib25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1080\/14728222.2024.2416975","article-title":"Progress and challenges in glypican-3 targeting for hepatocellular carcinoma therapy","volume":"28","author":"Couzinet","year":"2024","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.canlet.2026.218695_bib26","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3390\/ijms26052145","article-title":"Expression profiles of five common cancer membrane protein antigens collected for the development of cocktail CAR-T cell therapies applicable to Most solid cancer patients","volume":"26","author":"Nakatsura","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2026.218695_bib27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.3389\/fonc.2019.00248","article-title":"Next-generation cancer immunotherapy targeting Glypican-3","volume":"9","author":"Shimizu","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.canlet.2026.218695_bib28","first-page":"2657","article-title":"Usefulness of plasma full-length glypican-3 as a predictive marker of hepatocellular carcinoma recurrence after radial surgery","volume":"19","author":"Miura","year":"2020","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.canlet.2026.218695_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in hepatocellular carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.canlet.2026.218695_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2019.12.005","article-title":"Cross-presentation of exogenous antigens on MHC I molecules","volume":"64","author":"Colbert","year":"2020","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.canlet.2026.218695_bib31","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric antigen Receptor-Glypican-3 T-Cell therapy for advanced hepatocellular carcinoma: results of phase I trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2026.218695_bib32","doi-asserted-by":"crossref","first-page":"xii18","DOI":"10.1093\/annonc\/mdx238","article-title":"Mechanisms regulating T-cell infiltration and activity in solid tumors","volume":"28","author":"Lanitis","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.canlet.2026.218695_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002723","article-title":"Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead","volume":"9","author":"Kirtane","year":"2021","journal-title":"J. ImmunoTher. Cancer"},{"key":"10.1016\/j.canlet.2026.218695_bib34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1159\/000531820","article-title":"Multicenter phase II trial of lenvatinib plus hepatic intra-arterial infusion chemotherapy with cisplatin for advanced hepatocellular carcinoma: leopard","volume":"13","author":"Ikeda","year":"2024","journal-title":"Liver Cancer"},{"key":"10.1016\/j.canlet.2026.218695_bib35","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s00262-012-1366-6","article-title":"Intratumoral peptide injection enhances tumor cell antigenicity recognized by cytotoxic T lymphocytes: a potential option for improvement in antigen-specific cancer immunotherapy","volume":"62","author":"Nobuoka","year":"2013","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.canlet.2026.218695_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/cas.70023","article-title":"Feasibility of intratumoral administration with EPHB4-CAR-T cells for the treatment of oral squamous cell carcinoma","author":"Ito","year":"2025","journal-title":"Cancer Sci."},{"key":"10.1016\/j.canlet.2026.218695_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/tan.12536","article-title":"Determination of HLA\u2010A, \u2010C, \u2010B, \u2010DRB1 allele and haplotype frequency in Japanese population based on family study","volume":"85","author":"Ikeda","year":"2015","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.canlet.2026.218695_bib38","first-page":"D783","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.canlet.2026.218695_bib39","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2026.218695_bib40","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.canlet.2026.218695_bib41","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41573-025-01291-5","article-title":"In vivo chimeric antigen receptor (CAR)-T cell therapy","volume":"25","author":"Bot","year":"2026","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004593?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383526004593?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T20:21:03Z","timestamp":1785874863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383526004593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":41,"alternative-id":["S0304383526004593"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218695","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"T-cell receptor\u2013engineered T-cell therapy using a glypican-3\u2013specific TCR derived from a hepatoblastoma vaccine responder for HLA-A2\u2013positive glypican-3\u2013expressing cancers","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2026.218695","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"218695"}}